This approval represents a significant regulatory milestone, making Proliv™Rx the first and only at-home neuromodulation ...

Biohaven didn't receive the clinical readout it was hoping for over the festive period. | As the biopharma wound down for the ...

For individuals with major depressive disorder (MDD) that does not respond to pharmacotherapy, recent decisions by the U.S.

The wearable device delivers electrical impulses through a headset that can be administered by the patient at home under physician oversight.

Gilgamesh Pharma, a clinical-stage neuroscience company focused on transforming psychiatric treatment, today announced positive topline results from its Phase 2a study of blixeprodil (GM-1020).

An analysis of major depressive disorder, covering diagnostic criteria, prevalence statistics across demographics, and ...

Adding a daily fish oil supplement to psychotherapy showed no significant benefit over placebo for kids and teens with ...

Patients with first-episode MDD showed lower effective and functional connectivity between the anterior cingulate cortex and frontal regions.

Intra-Cellular Therapies’ surging antipsychotic Caplyta has scored again with remarkable trial results, fueling its bid for a third and potentially most lucrative indication—major depressive disorder ...

If you have depression (major depressive disorder), your primary care doctor will likely refer you to a mental health expert like a psychiatrist, a medical doctor who specializes in mental health, or ...